NCT02992938

Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia

Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: University of Chile · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Remifentanil is a potent opioid widely used during the administration of general anesthesia. There is a lot of evidence that suggest that the used of remifentanil is associated with the development of hyperalgesia (a reduction of nociceptive thresholds). However, the mechanism of this hyperalgesia is not fully understood. Recently, it was demonstrated that the disruption of the Cl- homeostasis could be involved. Interestingly, this was prevented in a murine model with the administration of Acetazolamide, a carbonic anhydrase inhibitor. In our clinical trial we will try to determine if the preoperative administration of acetazolamide could prevent the hyperalgesia induced by remifentanil in patients scheduled for thyroidectomy with general anesthesia.

Conditions

• Hyperalgesia
• Opioid-Related Disorders

Interventions

Type	Name	Description
DRUG	Acetazolamide
DRUG	Placebo Oral Tablet

Timeline

• Start date: 2016-12-01
• Primary completion: 2018-09-28
• Completion: 2018-09-28
• First posted: 2016-12-14
• Last updated: 2018-12-31

Locations

1 site across 1 country: Chile